Mass production of brain-computer interfaces to begin in 2026! The Hang Seng Medical ETF (159892) surged by 6%, with a 'brain-computer interface' exposure exceeding 20%. The Medical Device ETF (562600) rose by 5.6%.

Gelonghui, January 5 | On the first trading day of A-shares in 2026, the brain-computer interface sector experienced a strong surge. Component stocks such as Botuo Biotech, SinoMed, and Xiangyu Medical collectively hit the '20CM' limit-up mark, driving the medical device ETF up by 5.6%. The Hong Kong-listed medical sector also advanced across the board, with the Hang Seng Pharmaceuticals ETF and the HK Connect Healthcare ETF rising by 6% and 5.7%, respectively. Key developments include: (1) Elon Musk recently stated on social media that his brain-computer interface company Neuralink will begin 'mass production' of its devices in 2026. (2) According to CCTV, China approved 76 innovative drugs for marketing in 2025, surpassing the total of 48 in 2024, setting a new record high. Additionally, the total value of China’s outbound licensing deals for innovative drugs exceeded $130 billion in 2025, with over 150 transactions completed, also marking a new high. Open Source Securities believes that the anticipated scale production by Neuralink, coupled with automated surgical solutions, along with Merge’s advancement into next-generation ultrasound-based brain-computer interface technology, signals the transition from clinical validation to commercial scalability for brain-computer interfaces. Noteworthy products and their performance as of press time: Seizing innovation dividends in medical devices: Medical Device ETF (562600), +5.65%, tracks the CSI All-Share Medical Device Index, with an 89% allocation to the medical device industry and a 23.14% exposure to brain-computer interfaces, far exceeding other broad healthcare ETFs, precisely capturing growth opportunities in the medical device field. Representative of the global pharmaceutical industry chain: Hang Seng Pharmaceuticals ETF (159892), +6.07%, latest scale of 5.564 billion yuan, largest among similar products, top ten weightings include BeiGene, Wuxi Bio, Akeso, Sino Biopharm, and 3SBio. Focused on CXO and AI healthcare: HK Connect Healthcare ETF (520510), +5.72%, index concentration in CXO leads the market; key holdings include Wuxi Bio (CDMO leader), (a global frontrunner in bispecific antibody drug development), MicroPort (pioneer in domestic cardiovascular intervention solutions), and JD Health (leader in digital healthcare).